NVCR News and Press, NovoCure Limited From 08/28/23

2023-08-28 07:54:18 ET More on NovoCure NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure Limited ( NVCR ) Q2 2023 Earnings Call Transcript NovoCure Limited 2023 Q2 - Re...

Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analys...

2023-08-23 09:04:00 ET Summary NovoCure sells and develops devices intended to treat solid tumor cancers using physical forces related to electric fields. The firm’s sales growth ended in Q3-2020, and since then operating and net margins (LTM) have been deteriorating. Its n...

San Diego, California--(Newsfile Corp. - August 12, 2023) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, all dates inclusive (the "Class Period") have until A...

2023-08-09 10:45:00 ET Growth stocks have been top performers in 2023 after lagging behind value and dividend stocks in 2022. And despite the signs of a slowing global economy, growth stocks are expected to maintain their momentum in the near future, thanks to the sharp pullback in this ass...

2023-08-09 05:10:00 ET When it comes to oncology therapies, most people probably think about drugs, but NovoCure (NASDAQ: NVCR) has a radically different approach. Its portable anti-cancer device is already on the market, and it appears to be a helpful add-on treatment for glioblast...

2023-08-08 16:11:00 ET Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in price, in contrast to the 0.5% slump of the bellwether S&am...

2023-08-08 14:20:40 ET More on NovoCure NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure At 5 Year Lows: Avoid Or Opportunity? NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data ...

2023-07-28 10:46:23 ET Summary NovoCure reported a decrease in total net revenues for Q2 2023, primarily due to reduced U.S. claim collections. Research and development costs decreased, while sales and marketing expenses and general and administrative costs increased. The Phas...

2023-07-27 18:56:08 ET Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure 's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by almost 16% on the day due to worse-than-expected fundamentals f...